Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Clean (Unaudited with Limited Review Report - No qualifications or modifications noted)
Key Financial Highlights [₹ in Crores]:
Standalone Results:
Revenue from Operations: ₹2,986.92 crore (19.3% increase from ₹2,503.03 crore in Q1 FY26)
Total Income: ₹2,987.30 crore
EBITDA: ₹170.30 crore (14.1% increase from ₹149.26 crore in Q1 FY26)
Net Profit: ₹76.59 crore (44.9% increase from ₹52.85 crore in Q1 FY26)
EPS: ₹11.43 (Basic and Diluted)
Consolidated Results:
Revenue from Operations: ₹2,988.44 crore (19.4% increase from ₹2,503.12 crore in Q1 FY26)
Total Income: ₹2,988.82 crore
EBITDA: ₹169.94 crore (12.5% increase from ₹151.04 crore in Q1 FY26)
Net Profit: ₹96.83 crore (32.2% increase from ₹73.25 crore in Q1 FY26)
Net Profit attributable to Owners: ₹96.83 crore
EPS: ₹14.45 (Basic and Diluted)
Segment-wise Performance [₹ in Crores]:
Segment Revenue (Standalone):
- Bio-based Specialities and Performance Chemicals: ₹361.73 crore
- Potable Spirits: ₹2,218.67 crore
- Ennature Biopharma: ₹83.30 crore
- Bio-Fuel: ₹323.22 crore
Segment Results (Profit before Interest and Tax - Standalone):
- Bio-based Specialities and Performance Chemicals: ₹31.75 crore
- Potable Spirits: ₹75.03 crore
- Ennature Biopharma: ₹7.25 crore
- Bio-Fuel: ₹27.03 crore
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital raising activities announced in this meeting.
Other Significant Information:
Demerger Update:
The National Company Law Tribunal (NCLT) sanctioned the Composite Scheme of Arrangement on July 17, 2026, involving:
- Demerger of Bio Pharma undertaking into Ennature Bio Pharma Limited
- Demerger of Spirits & Biofuel undertaking into IGL Spirits Limited
- Both demerged entities to be listed on stock exchanges
- Appointed date: April 1, 2026
- The certified true copy of the NCLT Order is awaited
The company provided key details for the three companies for the quarter ended June 30, 2026:
- India Glycols Limited: Revenue ₹354.64 crore, EBITDA ₹40.22 crore
- IGL Spirits Limited: Revenue ₹2,541.89 crore, EBITDA ₹120.10 crore
- Ennature Bio Pharma Limited: Revenue ₹90.39 crore, EBITDA ₹9.98 crore
The above events are noted to have no impact on the current financial results.
Other Notes:
- Standalone Other Income for quarter ended March 31, 2026 includes Dividend Income of ₹38.58 crore from Subsidiary & Joint Venture companies
- Previous period figures have been restated/regrouped for comparability
- Paid-up Equity Share Capital: ₹33.51 crore (Face value ₹5/- each)
- Consolidated Other Equity: ₹2,899.27 crore (as of March 31, 2026)
Entities in Consolidation:
The consolidated results include:
- IGL Finance Limited
- IGL Chem International Pte. Ltd., Singapore
- IGL Chem International USA LLC
- IGL Chemicals And Services Private Limited
- Ennature Bio Pharma Limited
- IGL Spirits Limited
- Joint Venture: Clariant IGL Specialty Chemicals Private Limited (Share of net profit: ₹20.60 crore)